Experimental Gene Therapy Slows Huntington's Disease By 75%

Experimental Gene Therapy Slows Huntington's Disease TreatmentBy Shows 75% Slowing in Trial

Published SEP 24 2025

Experimental Gene Therapy Slows Huntington's Disease By 75%

story

Image credit: Unsplash

The Spin

WhileThis promising,is thisthe expensivefirst successful treatment requiringto complexslow 18-hourthe brainprogression surgeryof willHuntington's remaindisease inaccessibleafter todecades mostof patientsfailed who need itattempts. The results75% comereduction fromin onlydisease 29advancement means patients withoutcan peermaintain review,independence and thequality therapyof doesn'tlife curefor theyears diseaselonger butthan merelypreviously delayspossible. inevitableOne decline.patient Geneeven therapiesreturned oftento carrywork heftyafter priceundergoing tagsmedical retirement, proving that healthcarethis systemstherapy struggledelivers toreal-world affordbenefits beyond clinical measurements.

BBC News

While promising, this expensive treatment requiring complex 18-hour brain surgery will remain inaccessible to most patients who desperately need it. The results are based on only 29 patients without peer review, and the therapy doesn't cure the disease but merely delays the inevitable, gradual decline. Gene therapies often carry hefty price tags that healthcare systems struggle to afford, further exacerbating inequalities in access to care.

Guardian

Metaculus Prediction

There's a 50% chance that a vaccine for any major neurodegenerative disease will receive regulatory approval by February 2037, according to the Metaculus prediction community.